Edward Stelmakh

Edward Stelmakh discloses dealings in OptimizeRx Corp to SEC (Form 4). Over a trading history stretching from 15 August 2022 to 21 August 2026, the count stands at 29 filings.

The open-market side counts 1 purchase for €46k alongside 1 sale for €16k. Netting one side against the other leaves €30k of net buying. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 16 share grants and 11 option exercises.

Most recently, on 24 August 2026, the filings show a share grant worth €9,106 in OptimizeRx Corp. The clock since the last published purchase (17 August 2022) now reads 1,529 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.